Drug Type Fc fusion protein |
Synonyms MP 2021, MP2021 |
Target |
Action inhibitors |
Mechanism TM4SF19 inhibitors(transmembrane 4 L six family member 19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bone metastases | Preclinical | South Korea | 01 Oct 2025 | |
| Osteoporosis | Preclinical | South Korea | 01 Jul 2025 | |
| Rheumatoid Arthritis | Preclinical | South Korea | 14 Nov 2023 |






